Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients

Zumárraga, Mercedes; Dávila, Ricardo; Basterreche, Nieves; Arrúe, Aurora; Goienetxea, Biotza; Zamalloa, María Isabel; Erkoreka, Leire; Bustamante, Sonia; Inchausti, Lucía; González‐Torres, Miguel Ángel; Guimón, José

doi:10.1016/j.neuint.2010.02.015

Cited by 22 publications

(9 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent findings of increased concentrations of 3-methoxy-4-hydroxyphenylglycol (MHPG) in cerebrospinal fluid (CSF) and plasma have been reported in schizophrenia patients (Bjerkenstedt et al, 1985;Pickar et al, 1990;Zumarraga et al, 2010). Zumárraga et al (Zumarraga et al, 2010) found elevated levels of MHPG in schizophrenia compared to bipolar patients. However, decreased levels of CSF homovanillic acid (HVA) have also been reported (Bjerkenstedt et al, 1985;Peters, 1979).…”

Section: Other Metabolites (Table 3)mentioning

confidence: 83%

A systematic review of metabolite biomarkers of schizophrenia

Davison

O’Gorman

Brennan

et al. 2018

Schizophrenia Research

128

View full text Add to dashboard Cite

Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more objective biological measurement and medical diagnostic tests are not presently available. The use of metabolomics in the discovery of disease biomarkers has grown in recent years. Metabolomic methods could aid in the discovery of diagnostic biomarkers of schizophrenia. This systematic review focuses on biofluid metabolites associated with schizophrenia. A systematic search of Web of Science and Ovid Medline databases was conducted and 63 studies investigating metabolite biomarkers of schizophrenia were included. A review of these studies revealed several potential metabolite signatures of schizophrenia including reduced levels of essential polyunsaturated fatty acids (EPUFAs), vitamin E and creatinine; and elevated levels of lipid peroxidation metabolites and glutamate. Further research is needed to validate these biomarkers and would benefit from large cohort studies and more homogeneous and well-defined subject groups.

show abstract

Section: Other Metabolites (Table 3)mentioning

confidence: 83%

A systematic review of metabolite biomarkers of schizophrenia

Davison

O’Gorman

Brennan

et al. 2018

Schizophrenia Research

128

View full text Add to dashboard Cite

show abstract

“…In the catechol-O-methyltransferase gene there is a single nucleotide polymorphism, the Val158Met [35], which influences the activity of the enzyme it codifies. Results of a previous study [36] seem to indicate that the Val158Met genotype, associated with high enzyme activity (ValVal), is associated with a higher concentration of pHVA both in healthy control groups and in patients with schizophrenia without medication. Other polymorphisms in this gene with the same functional significance, as the one found in promoter P2 [37], could also influence the concentration of this metabolite.…”

Section: Individual Stability In Phva Valuesmentioning

confidence: 87%

Variability of Plasma Homovanillic Acid Over 13 Months in Patients with Schizophrenia; Relationship with the Clinical Response and the Wisconsin Card Sort Test

et al. 2011

Self Cite

View full text Add to dashboard Cite

In the present study we have measured, on a monthly basis, the concentration of plasma homovanillic acid (pHVA) in schizophrenic patients during 13 months of their pharmacological treatment. The average pHVA values of each patient were within the range of 7.30-17.70 ng/ml and the coefficients of variation for each patient (CV %) were within the range of 13-33%. Half of the patients that showed higher pHVA CV% values also showed higher scores on the Brief Psychiatric Rating Scale at the beginning of the study, and improved more after 6 months, when compared to the remaining 50% with lower CV% values. There was no significant relationship between the scores of the Wisconsin Card Sort Test and the concentration or the CV% of the pHVA of each patient. A greater variability in the pHVA may be associated with a greater plasticity of the dopaminergic system and a better clinical response.

show abstract

“…Numerous studies have obtained the major metabolite of norepinephrine, 3-methoxy-4-hydroxyphenylglycol (MHPG) as measure of increased sympathetic nervous system activity [12][13][14][15]. Much speculation exists pertaining to saliva versus plasma MHPG sampling to indicate increased sympathetic activity.…”

Section: Introductionmentioning

confidence: 99%